{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05794659",
            "orgStudyIdInfo": {
                "id": "PN-201-22"
            },
            "organization": {
                "fullName": "Aston Sci. Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "Adjuvant Therapeutic Cancer Vaccine (AST-201, pUMVC3-hIGFBP-2) in Patients With Advanced Ovarian Cancer",
            "officialTitle": "A Randomized Phase 2 Study to Evaluate the Efficacy and Safety for Adjuvant Therapeutic Cancer Vaccine (AST-201, pUMVC3-hIGFBP-2) in Patients With Advanced Ovarian Cancer (Cornerstone-004)",
            "acronym": "Cornerstone4",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "adjuvant-therapeutic-cancer-vaccine-ast-higfbp-in-patients-with-advanced-ovarian-cancer"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-07",
            "overallStatus": "NOT_YET_RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-11-15",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-11-15",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-11-15",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-03-07",
            "studyFirstSubmitQcDate": "2023-03-20",
            "studyFirstPostDateStruct": {
                "date": "2023-04-03",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-07-18",
            "lastUpdatePostDateStruct": {
                "date": "2023-07-20",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Aston Sci. Inc.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this phase 2 study is to assess the efficacy and safety for adjuvant therapeutic cancer vaccine AST-201 (pUMVC3-hIGFBP-2) in patients with newly diagnosed homologous-recombination proficient(HRP) advanced ovarian cancer (Stage III) after debulking surgery. Patients will receive AST-201 with rhuGM-CSF(Colony Stimulating Factor) or placebo with rhuGM-CSF in combination with standard adjuvant chemotherapy(Paclitaxel/Carboplatin).",
            "detailedDescription": "The study will comprise a screening period of -28 Days prior to initiation of study treatment (Day 1); an enrollment period of 24 months; the treatment duration will be approximately of 5 months.\n\nThe study will evaluate whether the addition of AST-201/rhuGM-CSF to the standard adjuvant chemotherapy will extend the Progression Free Survival(PFS) rate. Survival follow-up will be performed every 3 months (\u00b114 days) after the End of treatment (EOT) visit for 2 years after randomization and every 6 months (\u00b128 days) thereafter until disease progression or death from any cause or withdrawal of consent whichever comes first. Survival follow-up visits will be conducted by telephone, in-person visit, or chart review. The end of study (EOS) is defined as 2 years after the date of last patient enrollment."
        },
        "conditionsModule": {
            "conditions": [
                "Advanced Ovarian Cancer"
            ],
            "keywords": [
                "cancer vaccine",
                "phase 2 study",
                "Advanced ovarian cancer",
                "homologous-recombination proficient (HRP)"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "interventionModelDescription": "Single blind, randomized, placebo-controlled, multicenter, phase 2 clinical study",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "SINGLE",
                    "maskingDescription": "Single blinded",
                    "whoMasked": [
                        "PARTICIPANT"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 98,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "AST-301",
                    "type": "EXPERIMENTAL",
                    "description": "AST-201 with rhuGM-CSF (3-week interval, 3 cycles in total)\n\nStandard chemotherapy (paclitaxel/carboplatin) (3-week interval, 6 cycles in total)\n\n\\* Both AST-201/rhuGM-CSF or Placebo/rhuGM-CSF will be given intradermally 2 weeks after each combination chemotherapy (on Day 15 of each cycle) for 3 cycles",
                    "interventionNames": [
                        "Biological: AST-201",
                        "Drug: Paclitaxel",
                        "Drug: Carboplatin",
                        "Drug: rhuGM-CSF(Granulocyte-Macrophage Colony-Stimulating Factor)"
                    ]
                },
                {
                    "label": "Placebo",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Placebo with rhuGM-CSF (3-week interval, 3 cycles in total)\n\nStandard chemotherapy (paclitaxel/carboplatin) (3-week interval, 6 cycles in total)\n\n\\*Both AST-201/rhuGM-CSF or Placebo/rhuGM-CSF will be given intradermally 2 weeks after each combination chemotherapy (on Day 15 of each cycle) for 3 cycles",
                    "interventionNames": [
                        "Drug: Paclitaxel",
                        "Drug: Carboplatin",
                        "Drug: Placebo",
                        "Drug: rhuGM-CSF(Granulocyte-Macrophage Colony-Stimulating Factor)"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "BIOLOGICAL",
                    "name": "AST-201",
                    "description": "i.d. (3-week interval, 3 cycles in total)",
                    "armGroupLabels": [
                        "AST-301"
                    ],
                    "otherNames": [
                        "pUMVC3-hIGFBP-2 multi-epitope plasmid DNA vaccine"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Paclitaxel",
                    "description": "3-week interval, 6 cycles in total",
                    "armGroupLabels": [
                        "AST-301",
                        "Placebo"
                    ],
                    "otherNames": [
                        "Taxol"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Carboplatin",
                    "description": "3-week interval, 6 cycles in total",
                    "armGroupLabels": [
                        "AST-301",
                        "Placebo"
                    ],
                    "otherNames": [
                        "Paraplatin"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Placebo",
                    "description": "i.d. (3-week interval, 3 cycles in total)",
                    "armGroupLabels": [
                        "Placebo"
                    ],
                    "otherNames": [
                        "Normal saline (USP)"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "rhuGM-CSF(Granulocyte-Macrophage Colony-Stimulating Factor)",
                    "description": "i.d. (3-week interval, 3 cycles in total)",
                    "armGroupLabels": [
                        "AST-301",
                        "Placebo"
                    ],
                    "otherNames": [
                        "sargramostim",
                        "Leukine"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Progression-Free Survival (PFS)",
                    "description": "the time from the date of randomization to disease progression, or death from any cause whichever occurs first",
                    "timeFrame": "overall study duration (approximately 48 months)"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "2-year PFS rate",
                    "description": "proportion of patients alive without disease progression or death at two years after the randomization",
                    "timeFrame": "24months from the first dose of AST-301 administration"
                },
                {
                    "measure": "Overall Survival (OS)",
                    "description": "the time from the date of randomization to death from any cause",
                    "timeFrame": "overall study duration (approximately 48 months)"
                },
                {
                    "measure": "AST-201 specific immunogenicity by Interferon gamma (IFN-gamma) enzyme-linked immunospot (ELISpot )",
                    "description": "AST-201 specific IFN-gamma ELISpot",
                    "timeFrame": "17months"
                },
                {
                    "measure": "Number of participants with Adverse events as graded by the National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] version 5.0)",
                    "description": "Adverse events (AEs) Treatment-emergent adverse events (TEAEs) Serious adverse events (SAEs) Vital signs Physical examination Eastern Cooperative Oncology Group (ECOG) performance status Electrocardiogram (ECG) test Laboratory tests",
                    "timeFrame": "5 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Newly diagnosed stage III (FIGO classification) epithelial ovarian cancer including primary peritoneal cancer, fallopian-tube cancer\n* Has received upfront surgery and optimally debulked(a residual tumor less than 1 cm)\n* Can start adjuvant therapy within 6 weeks of debulking surgery\n* Has Homologous Recombination Proficiency (HRP) tumor defined by FDA-approved testing\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Demonstrates adequate organ function.\n\nExclusion Criteria:\n\n* Has a history of hypersensitivity or other contraindications to rhuGM-CSF\n* Has a history of active malignancy \u22645 years prior to first administration of investigational drug except for adequately treated non-melanoma skin cancer or epithelial carcinoma without evidence of disease\n* Is on immune suppression therapy or has a history of immune suppression therapy \u22644 weeks prior to the first administration of investigational drugs\n* Has active or prior autoimmune disease or inflammatory disease\n* Has active infectious disease including tuberculosis, hepatitis B, hepatitis C or human immunodeficiency virus (HIV) infection\n* Is pregnant or breastfeeding or expecting to conceive children within the projected duration of the study",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Hyunwon Shin, MD, PhD",
                    "role": "CONTACT",
                    "phone": "+82-2-2038-2347",
                    "email": "hyunwon.shin@astonsci.com"
                },
                {
                    "name": "Eunkyo Joung, MD, CMO",
                    "role": "CONTACT",
                    "phone": "+82-2-2038-2347",
                    "email": "eunkyo.joung@astonsci.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Hyunwon Shin, MD, PhD",
                    "affiliation": "hyunwon.shin@astonsci.com",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "University of Washington",
                    "city": "Seattle",
                    "state": "Washington",
                    "zip": "98109",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "John B. Liao, MD, PhD",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 47.60621,
                        "lon": -122.33207
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000010051",
                    "term": "Ovarian Neoplasms"
                },
                {
                    "id": "D000077216",
                    "term": "Carcinoma, Ovarian Epithelial"
                }
            ],
            "ancestors": [
                {
                    "id": "D000004701",
                    "term": "Endocrine Gland Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000010049",
                    "term": "Ovarian Diseases"
                },
                {
                    "id": "D000000291",
                    "term": "Adnexal Diseases"
                },
                {
                    "id": "D000005831",
                    "term": "Genital Diseases, Female"
                },
                {
                    "id": "D000052776",
                    "term": "Female Urogenital Diseases"
                },
                {
                    "id": "D000005261",
                    "term": "Female Urogenital Diseases and Pregnancy Complications"
                },
                {
                    "id": "D000091642",
                    "term": "Urogenital Diseases"
                },
                {
                    "id": "D000005833",
                    "term": "Genital Neoplasms, Female"
                },
                {
                    "id": "D000014565",
                    "term": "Urogenital Neoplasms"
                },
                {
                    "id": "D000091662",
                    "term": "Genital Diseases"
                },
                {
                    "id": "D000004700",
                    "term": "Endocrine System Diseases"
                },
                {
                    "id": "D000006058",
                    "term": "Gonadal Disorders"
                },
                {
                    "id": "D000002277",
                    "term": "Carcinoma"
                },
                {
                    "id": "D000009375",
                    "term": "Neoplasms, Glandular and Epithelial"
                },
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M12974",
                    "name": "Ovarian Neoplasms",
                    "asFound": "Ovarian Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M1704",
                    "name": "Carcinoma, Ovarian Epithelial",
                    "asFound": "Ovarian Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M7863",
                    "name": "Endocrine Gland Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M12972",
                    "name": "Ovarian Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M3643",
                    "name": "Adnexal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8943",
                    "name": "Genital Diseases, Female",
                    "relevance": "LOW"
                },
                {
                    "id": "M2876",
                    "name": "Genital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M2875",
                    "name": "Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M27093",
                    "name": "Female Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14127",
                    "name": "Pregnancy Complications",
                    "relevance": "LOW"
                },
                {
                    "id": "M8399",
                    "name": "Female Urogenital Diseases and Pregnancy Complications",
                    "relevance": "LOW"
                },
                {
                    "id": "M8945",
                    "name": "Genital Neoplasms, Female",
                    "relevance": "LOW"
                },
                {
                    "id": "M17315",
                    "name": "Urogenital Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M7862",
                    "name": "Endocrine System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M9163",
                    "name": "Gonadal Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M12320",
                    "name": "Neoplasms, Glandular and Epithelial",
                    "relevance": "LOW"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "T4352",
                    "name": "Ovarian Cancer",
                    "asFound": "Ovarian Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "T4354",
                    "name": "Ovarian Epithelial Cancer",
                    "asFound": "Ovarian Cancer",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                },
                {
                    "abbrev": "BC19",
                    "name": "Gland and Hormone Related Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000017239",
                    "term": "Paclitaxel"
                },
                {
                    "id": "D000016190",
                    "term": "Carboplatin"
                },
                {
                    "id": "C000082430",
                    "term": "Molgramostim"
                },
                {
                    "id": "C000081222",
                    "term": "Sargramostim"
                }
            ],
            "ancestors": [
                {
                    "id": "D000007155",
                    "term": "Immunologic Factors"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000000972",
                    "term": "Antineoplastic Agents, Phytogenic"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000050257",
                    "term": "Tubulin Modulators"
                },
                {
                    "id": "D000050256",
                    "term": "Antimitotic Agents"
                },
                {
                    "id": "D000050258",
                    "term": "Mitosis Modulators"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M18650",
                    "name": "Carboplatin",
                    "asFound": "System",
                    "relevance": "HIGH"
                },
                {
                    "id": "M257633",
                    "name": "Molgramostim",
                    "asFound": "Always",
                    "relevance": "HIGH"
                },
                {
                    "id": "M219218",
                    "name": "Sargramostim",
                    "asFound": "Always",
                    "relevance": "HIGH"
                },
                {
                    "id": "M19537",
                    "name": "Paclitaxel",
                    "asFound": "Sessions",
                    "relevance": "HIGH"
                },
                {
                    "id": "M17360",
                    "name": "Vaccines",
                    "relevance": "LOW"
                },
                {
                    "id": "M231",
                    "name": "Albumin-Bound Paclitaxel",
                    "relevance": "LOW"
                },
                {
                    "id": "M10201",
                    "name": "Immunologic Factors",
                    "relevance": "LOW"
                },
                {
                    "id": "M26197",
                    "name": "Tubulin Modulators",
                    "relevance": "LOW"
                },
                {
                    "id": "M26196",
                    "name": "Antimitotic Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}